By the Top Tier Newswire AI Desk · November 16, 2026 at 12:36 PM ET · reviewed against 10 wire stories
CG ONCOLOGY INC (CGON) is up +16.16% in the latest session. Our newswire has captured 10 stories on CGON across 7 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
CG Oncology (CGON) shares rose 16.16% to $86.43, driven by positive topline results from its Phase 3 PIVOT-006 trial. The data showed that the company’s experimental bladder cancer therapy, cretostimogene, reduced the risk of recurrence by 68% compared to surveillance.
What Happened
CG Oncology announced that its Phase 3 PIVOT-006 registrational trial met its primary endpoint. The results indicated a 68% lower recurrence risk for non-muscle invasive bladder cancer (NMIBC) versus a control group, with a hazard ratio of 0.32. The company plans to complete a Biologics License Application (BLA) submission for BCG-unresponsive NMIBC in March 2027. A second BLA for intermediate-risk Ta NMIBC is projected for the second quarter of 2027. Jones raised its price target for the stock to $112 from $85 following the announcement.
What The Data Shows
The stock opened at $73.29, a 1.5% gap down from the prior close of $74.40. It reached a session high of $107.58 at 8:05 AM ET before settling near $86.69. Volume so far stands at 4.3 million shares, which is 4.5 times the three-month daily average. The move pushed the stock to a fresh 52-week high, while the 52-week range remains $37.01 to $80.97. The company has a market cap of $6.6 billion and is currently unprofitable with a trailing twelve-month EPS of -2.78. Revenue grew 183.6% over the same period. Over the last 8 sessions, the stock had already moved up 9.9% from $67.71 to $74.40. Recent insider activity includes three sales totaling $210,000 by director Leonard E. Post, with the most recent filing on October 19, 2026.
What To Watch
The next major catalyst is the planned BLA submission for BCG-unresponsive NMIBC in March 2027. Investors will also monitor the timeline for the second BLA submission, which is expected in the second quarter of 2027.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
CGON · Nov 16 session (5-min) · +13.55% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 10 stories · 68/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
4d agoThe FlyBULLISH 64Analyst
CG Oncology price target raised to $112 from $85 at Jones
4d agoThe FlyBULLISH 64General
CG Oncology rises 11.6%
4d agoGuruFocusBULLISH 74Product/PR
CG Oncology (CGON) Reports Positive Phase 3 Trial Data for Bladder Cancer Therapy
4d agoSeeking AlphaBULLISH 74Product/PR
CG Oncology rises on phase 3 data for bladder cancer immunotherapy
CG Oncology's phase 3 PIVOT-006 trial shows 68% lower NMIBC recurrence risk versus surveillance, supporting a second BLA submission projected for Q2 2027. Read more here.
4d agoThe FlyBULLISH 74Product/PR
CG Oncology announces Phase 3 PIVOT-006 trial met primary endpoint
4d agoInvestors.comBULLISH 74General
CG Oncology Exceeds Even The 'Most Bullish Conversations;' Shares Break Out
CG Oncology said Monday its experimental bladder cancer treatment cut the risk of recurrence by 68%.
4d agoThe FlyBULLISH 64General
Cg Oncology Rises 12 1
4d agoTipRanksBULLISH 74Product/PR
CG Oncology Reports Positive Phase 3 Bladder Cancer Trial Results
CG Oncology, Inc. ( ($CGON) ) has provided an announcement. On November 16, 2026, CG Oncology announced topline results from its Phase 3 PIVOT-006 registrational tr...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →